Female carriers of a pathogenic variant (PV) in breast cancer (BRCA)1 or BRCA2 gene are at high lifetime risk of developing breast (around 70%) and ovarian cancer (around 44% and 17% for BRCA1/2-PV carriers respectively) [1]. This evidence concerns the gene BRCA2 and breast carcinoma.